10 results
8-K
EX-99.1
DYAI
Dyadic International Inc., DE
12 Apr 23
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
8:30am
Emalfarb, Dyadic’s CEO.
“Rubic’s mission is to develop a solution for the discovery, development, evaluation and manufacture of high-quality, cost
8-K
EX-99.1
DYAI
Dyadic International Inc., DE
10 Nov 21
Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress
4:16pm
in 2022 — independently and/or potentially through our global network of development partners. Dyadic’s mission since the DuPont transaction has been
8-K
EX-99.1
r14g007n7f019t98h0x
11 Aug 21
Entry into a Material Definitive Agreement
8:32am
8-K
EX-99.1
a61vk5i6
27 Jul 21
Other Events
8:31am
8-K
EX-99.1
o7ckqaeqbd 2b6mp
8 May 19
Dyadic and Serum Institute of India to Develop and Manufacture Globally Affordable and Accessible Antibody Products and Vaccines
4:26pm
8-K
EX-99.1
rjb j6kv1x
8 May 19
Dyadic Announces Sub-Licensing Agreement with Alphazyme
3:15pm
8-K
EX-99.1
xojt4ui8c3
2 May 19
Dyadic Announces Sub-Licensing Agreement with Luina Bio
4:05pm
- Prev
- 1
- Next